IHS Chemical Week

Regions :: Western Europe :: U.K.

Denmark's Novo acquires Xellia Pharmaceuticals in $700-million deal

9:09 AM MDT | May 22, 2013 | Francinia Protti-Alvarez

Novo A/S (Hellerup, Denmark), parent of pharmaceutical firm Novo Nordisk (Bagsvaerd, Denmark), has acquired Xellia Pharmaceuticals (Oslo) from private equity firm 3i (London) for an enterprise value of $700 million, 3i and Novo have announced. The company 3i says it reaped a 2.3-times return on the original $395-million investment made in 2008. The closing of the transaction will be subject to relevant competition law approvals and is expected to take place during the third quarter of 2013. "Xellia strongly complements our portfolio of significant...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa